Personal information

Activities

Collapse all

Works (14)

Early HBcrAg and Anti‐HBc Levels Identify Patients at High Risk for Severe Flares After Nucleos(t)ide Analogue Cessation—A Pooled Analysis of Two Clinical Trials

Alimentary Pharmacology & Therapeutics
2025-02 | Journal article
DOI: 10.1111/apt.18416
Contributors: Edo J. Dongelmans; Jordan J. Feld; André Boonstra; Sylvia M. Brakenhoff; David Wong; Colina Yim; Mark Claassen; Pieter Honkoop; Bettina E. Hansen; Robert A. de Man et al.
Source: check_circle
Crossref

Socio‐economic factors associated with loss to follow‐up among individuals with HCV: A Dutch nationwide cross‐sectional study

Liver International
2024-01 | Journal article
DOI: 10.1111/liv.15729
Contributors: Marleen van Dijk; Anders Boyd; Sylvia M. Brakenhoff; Cas J. Isfordink; Rosan A. van Zoest; Mark D. Verhagen; Robert J. de Knegt; Joost P. H. Drenth; Marc van der Valk
Source: check_circle
Crossref

Lower pre-treatment hbv dna levels are associated with better off-treatment outcomes after Nucleo(S)Tide analogue withdrawal in patients with hbeag negative chronic hepatitis B: A multicenter cohort study

JHEP Reports
2023-05 | Journal article
DOI: 10.1016/j.jhepr.2023.100790
Contributors: Milan J. Sonneveld; Shao-Ming Chiu; Jun Yong Park; Sylvia M. Brakenhoff; Apichat Kaewdech; Wai-Kay Seto; Yasuhito Tanaka; Ivana Carey; Margarita Papatheodoridi; Piero Colombatto et al.
Source: check_circle
Crossref

Use of HBV RNA and to predict change in serological status and disease activity in CHB

Hepatology
2023-04-20 | Journal article
DOI: 10.1097/HEP.0000000000000413
Contributors: Marc G. Ghany; Wendy C. King; Amanda S. Hinerman; Anna SF. Lok; Mauricio Lisker-Melman; Raymond T. Chung; Norah Terrault; Harry L.A. Janssen; Mandana Khalili; William M. Lee et al.
Source: check_circle
Crossref

End-of-treatment HBsAg, HBcrAg and HBV RNA predict the risk of off-treatment ALT flares in chronic hepatitis B patients

Journal of Microbiology, Immunology and Infection
2023-02 | Journal article
DOI: 10.1016/j.jmii.2022.06.002
Contributors: Sylvia M. Brakenhoff; Robert J. de Knegt; Margo J.H. van Campenhout; Annemiek A. van der Eijk; Willem P. Brouwer; Florian van Bömmel; André Boonstra; Bettina E. Hansen; Thomas Berg; Harry L.A. Janssen et al.
Source: check_circle
Crossref

Patients treated with rituximab are poorly screened for hepatitis B infection: Data from a low-incidence country

European Journal of Internal Medicine
2023-02 | Journal article
DOI: 10.1016/j.ejim.2022.11.024
Contributors: Sylvia M Brakenhoff; Roos Hoekstra; Pieter Honkoop; Robert Roomer; Jan G den Hollander; Geert Bezemer; Robert J de Knegt; Milan J Sonneveld; Robert A de Man
Source: check_circle
Crossref

Epidemiology and management of hepatitis B and C in primary care in the Netherlands: data from the Rijnmond Primary Care database

Family Practice
2023-02-09 | Journal article
DOI: 10.1093/fampra/cmac070
Contributors: Sylvia M Brakenhoff; Robert A de Man; Robert J de Knegt; Patrick J E Bindels; Evelien I T de Schepper
Source: check_circle
Crossref

Time-trends in disease characteristics and comorbidities in patients with chronic hepatitis B in the period 1980–2020

European Journal of Internal Medicine
2023-01 | Journal article
DOI: 10.1016/j.ejim.2022.11.012
Contributors: D.P.C. van der Spek; W.K. Katwaroe; L.A. van Kleef; S. Brakenhoff; R.A. de Man; R.J. de Knegt; A.J. van der Meer; M.J. Sonneveld
Source: check_circle
Crossref

Levels of Antibodies to Hepatitis B Core Antigen Are Associated With Liver Inflammation and Response to Peginterferon in Patients With Chronic Hepatitis B

The Journal of Infectious Diseases
2022-12-28 | Journal article
DOI: 10.1093/infdis/jiac210
Contributors: Sylvia M Brakenhoff; Robert J de Knegt; Jeffrey Oliveira; Annemiek A van der Eijk; Anneke J van Vuuren; Bettina E Hansen; Harry L A Janssen; Robert A de Man; André Boonstra; Milan J Sonneveld
Source: check_circle
Crossref

Assessment of Adherence to Clinical Guidelines in Patients with Chronic Hepatitis B

Viruses
2022-10-11 | Journal article
DOI: 10.3390/v14102229
Contributors: Warshan K. Katwaroe; Sylvia M. Brakenhoff; Daniël P. C. van der Spek; Robert J. de Knegt; Laurens A. van Kleef; Robert A. de Man; Adriaan J. P. van der Meer; Milan J. Sonneveld
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels

Journal of Hepatology
2022-01 | Journal article
DOI: 10.1016/j.jhep.2022.01.007
Contributors: M.J. Sonneveld; S.-M. Chiu; J.Y. Park; S.M. Brakenhoff; A. Kaewdech; W.K. Seto; Y. Tanaka; I. Carey; M. Papatheodoridi; F. van Bömmel et al.
Source: check_circle
Crossref

Effects of on‐treatment ALT flares on serum HBsAg and HBV RNA in patients with chronic HBV infection

Journal of Viral Hepatitis
2021-12 | Journal article
DOI: 10.1111/jvh.13613
Contributors: Hannah S. J. Choi; Milan J. Sonneveld; Mina S. Farag; Willem P. Brouwer; Sylvia M. Brakenhoff; Grishma Hirode; Adam J. Gehring; Rob A. de Man; Bettina E. Hansen; Harry L. A. Janssen
Source: check_circle
Crossref

Editorial: HBV cure—the quest for biomarkers to predict off‐treatment sustained response. Authors' reply

Alimentary Pharmacology & Therapeutics
2021-02 | Journal article
DOI: 10.1111/apt.16233
Contributors: Sylvia M. Brakenhoff; Robert A. de Man; Robert J. de Knegt; Harry L. A. Janssen; Milan J. Sonneveld
Source: check_circle
Crossref

Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss

Alimentary Pharmacology & Therapeutics
2021-01 | Journal article
DOI: 10.1111/apt.16172
Contributors: Sylvia M. Brakenhoff; Robert A. de Man; André Boonstra; Margo J. H. van Campenhout; Robert J. de Knegt; Florian van Bömmel; Annemiek A. van der Eijk; Thomas Berg; Bettina E. Hansen; Harry L. A. Janssen et al.
Source: check_circle
Crossref
How many people are using ORCID?